BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
The company's lead drug Azelaprag, is an orally available small molecule that has been well-tolerated in 265 individuals across eight Phase 1 clinical trials.BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 million in an initial public offering.
專注於開發代謝性疾病治療方法的生物年齡實驗室公司，提交了SEC備案文件，計劃在首次公開募股中最多籌集10000萬美元。
The company was founded in 2015 and plans to list on the Nasdaq under the symbol BIOA. BioAge Labs filed confidentially on May 31, 2024.
該公司成立於2015年，計劃在納斯達克上市，股票代碼爲BIOA。BioAge Labs於2024年5月31日進行了保密文件備案。
Goldman Sachs, Morgan Stanley, Jefferies, and Citi are the joint bookrunners on the deal. No pricing terms were disclosed.
高盛、摩根士丹利、Jefferies和Citi是該交易的聯席承銷商。沒有披露定價條款。
The company's lead drug Azelaprag, is an orally available small molecule that has been well-tolerated in 265 individuals across eight Phase 1 clinical trials.
公司的首席藥物Azelaprag是一種口服小分子，已在八項一期臨床試驗中的265名患者中得到了良好的耐受性。
Also Read: Newly Listed Obesity Player Fractyl Health Shares Encouraging Preclinical Data.
此外，也有報道稱：新上市的肥胖治療公司Fractyl Health分享了令人鼓舞的臨床前數據。
In preclinical obesity models, azelaprag demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while restoring healthy body composition and improving muscle function.
在臨床前肥胖模型中，azelaprag表現出能夠將胰高血糖素樣肽-1受體（GLP-1R）激動劑引起的減重效果超過一倍，並恢復健康的體組成和改善肌肉功能。
The company plans to assess azelaprag's potential to drive significant improvements in weight loss when combined with a GLP-1R agonist in two Phase 2 trials.
該公司計劃在兩個二期臨床試驗中評估azelaprag與GLP-1R激動劑聯合使用時在減重方面帶來的顯著改善。
The ongoing STRIDES clinical trial will assess azelaprag in combination with tirzepatide, marketed as Zepbound by Eli Lilly And Co (NYSE:LLY), with topline results anticipated in the third quarter of 2025.
正在進行的STRIDES臨床試驗將評估azelaprag與Eli Lilly And Co（紐交所代碼：LLY）推出的Zepbound（tirzepatide）的聯合使用，預計在2025年第三季度發佈最終結果。
The second Phase 2 trial will assess azelaprag in combination with semaglutide, marketed as Wegovy by Novo Nordisk A/S (NYSE:NVO), with initiation expected in the first half of 2025.
第二階段2試驗將評估與諾和諾德A/S (紐交所:NVO)的Wegovy（semaglutide的市場名稱）聯合使用的azelaprag，預計在2025年上半年開始
BioAge also intends to initiate an insulin sensitivity proof-of-concept trial of azelaprag monotherapy in the first half of 2025 to support potential indication expansion.
BioAge還計劃在2025年上半年啓動azelaprag單藥的胰島素敏感性概念驗證試驗，以支持潛在的適應症擴展
The company is also developing orally available small-molecule brain-penetrant NLRP3 inhibitors for diseases driven by neuroinflammation and anticipates submitting an Investigational New Drug application for an NLRP3 inhibitor in the second half of 2025 and, if cleared, initiating a Phase 1 trial in the first half of 2026.
該公司還正在開發可口服、小分子、能穿透血腦屏障的神經炎症相關腦炎原環受體3（NLRP3）抑制劑，預計在2025年下半年提交一項NLRP3抑制劑的新藥申請，並在2026年上半年啓動第一階段試驗（如果通過初審）
In February, BioAge Labs completed a Series D financing round of $170 million led by Sofinnova Investments.
BioAge Labs在2月份完成了一輪17000萬美元的D輪融資，由Sofinnova Investments領投
- Alibaba's Taobao and Tmall Launch New Tech Venture, Eyeing Global Market Growth.
- 阿里巴巴的淘寶和天貓推出新的科技創業公司，瞄準全球市場增長
Photo by Vidmir Rais via Pixabay
來自Pixabay的Vidmir Rais攝影作品
